Dehydroepiandrosterone for the treatment of systemic lupus erythematosus

REFERENCES

• PARKER LN: Control of adrenal androgen secretion. Endocrin. Metab. Clin. North Am. (1991) 20:401–421.
   PubMed Web of Science ®Google Scholar
• LONGCOPE C: Metabolism of dehydroepiandrosterone. Ann. NY Acad. Sri. (1995) 774:143–148.
   PubMed Web of Science ®Google Scholar
• EBELING P, KOIVISTO P: Physiological importance of dehydroepiandrosterone. Lancet (1994) 343:1479–1481.
   PubMed Web of Science ®Google Scholar
• DAYNES RA, DUDLEY DJ, ARANEO BA: Regulation of murine lymphokine production in vivo. II. Dehydroepi- androsterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Eur. j Immunol (1990) 20:793-802. One of a series of papers describing the complex immunomodulatory effects of DHEA in a murine model.
   Google Scholar
• DAYNES RA, ARANEO BA, DOWELL et al.: Regulation of murine lymphokine production in vivo. III. The lymphoid tissue microenvironment exerts regulatory influences over T helper cell function. Exp. Med. (1990) 171:979–996.
   Google Scholar
• DAYNES RA, ARANEO BA: Natural regulators of T-cell lymphokine production in vivo. j Immunother. (1992) 12:174–179.
   PubMedGoogle Scholar
• SUZUKI T, SUZUKI N, DAYNES RA et al.: Dehydroepiandrosterone enhances IL-2 production and cytotoxic effector function of human T cells. Clin. Immunol Immunopathol (1991) 61:202-211. •One of the most striking immunomodulatory effects of DHEA is its ability to enhance IL-2 production.
   Google Scholar
• VAN VOLLENHOVEN RF, MCGUIRE JL: Estrogen, progesterone, and testosterone: can they be used to treat autoimmune diseases? Cleveland Clinic Med. (1994) 61:276.
   Google Scholar
• LAHITA RG: Gender and age in lupus. In: Systemic lupus erythematosus Ord edition). Lahita RGH (Ed.), Academic Press, San Diego (1999):129.
   Google Scholar
• FAM A, IZSAK M, SAIPHOO C: SLE and Klinefelter's syndrome. Arthritis Rheum. •• (1980) 23:124–126.
   Google Scholar
• PETRI M, HOWARD D, REPKE J: Frequency of lupus flare in pregnancy. The Hopkins Lupus Pregnancy Center experience. Arthritis Rheum. (1991) 34:1538–1545.
   PubMed Web of Science ®Google Scholar
• JUNGERS E DOUGADOS M, PELISSIER M et al: Influence of oral contraceptive therapy on the activity of systemic lupus erythematosus. Arthritis Rheum. (1982) 25:618–623.
   Google Scholar
• LAHITA RG, BRADLOW HL, KUNKEL HG: Alterations of estrogen metabolism in systemic lupus erythematosus. Arthritis Rheum. (1979) 22:1195–1198.
   PubMed Web of Science ®Google Scholar
• LAHITA RG, KUNKEL, BRADLOW HL: Increased oxidation of testosterone in systemic lupus erythematosus. Arthritis Rheum. (1983) 26:1517–1521.
   Google Scholar
• JUNGERS E HAHOUL, PELISSIER C et al.: Low plasma androgens in women with active or quiescent systemic lupus erythematosus. Arthritis Rheum. (1982) 25:454–457.
   Google Scholar
• LAHITA RG, BRADLOW HL, GINZLER E et al: Low plasma androgens in women with systemic lupus erythematosus. Arthritis Rheum. (1987) 30:241–248.
   PubMed Web of Science ®Google Scholar
• ROUBINIAN JNR, PAPOIAN R, TALAL N: Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J. Gun. Invest. (1977) 59:1066–1070.
   Google Scholar
• AGNELLO V, PARISER K, GELL J et al:Preliminary observations on danazol therapy of systemic lupus erythematosus: Effects on DNA antibodies, thrombocytopenia and complement. J. Rheumatel (1983) 10:682–687.
   PubMed Web of Science ®Google Scholar
• DOUGADOS M, JOB-DESLANDRE, AMOR B et al: Danazol therapy in systemic lupus erythematosus. A one-year prospective controlled trial on 40 female patients. Clin. Trials J. (1987) 24:191.
   Google Scholar
• LAHITA RG, CHENG CY, MONDER C: Experience with 19-nortestosterone in the therapy of systemic lupus erythematosus: Worsened disease after treatment with 19-nortestosterone in men and lack of improving women. J. Rheumatel (1992) 19:547–555.
   Google Scholar
• LINKER-ISRAELI M, BAKKE AC, KITRIDOU RC et al: Defective production of interleukin-1 and interleukin-2 in patients with systemic lupus erythematosus (SLE). J. Lumina (1983) 130:2651–2655.
   Google Scholar
• ALCOCER-VARELA J, ALARCON-SEGOVIA D: Decreased production of and response to interleukin-2 by cultured lymphocytes from patients with systemic lupus erythematosus. I Chi]. Invest. (1982) 69:1388–1392.
   PubMed Web of Science ®Google Scholar
• MULLER B, GIMSA U, MITCHISON NA et al: Modulating the ThliTh2 balance in inflammatory arthritis. Springer Semi]. Immuriepathel (1998) 20:181–196.
   Google Scholar
• SUZUKI T, SUZUKI N, ENGLEMAN EG et al.: Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes from patients with systemic lupus erythematosus (SLE). Gun. Exper. (1995) 99:251-255. ••This study shows that the low productionof IL-2 by peripheral blood mononuclear cells from patients with SLE can be partially reversed by the addition of in vitro DHEA.
   Google Scholar
• LUCAS JA, AHMED AA, CASEY ML et al.: Prevention of autoantibody formation and prolonged survival in new Zealand Black/New Zealand White Fl mice fed dehydroisoandrosterone. I Clin. Invest. (1985) 75:2091-2093. ••DHEA was shown to prolong lifeexpectancy in the Fl mouse strain that spontaneously develops an SLE-like disease.
   Google Scholar
• MASTUNAGA A, MILLER BC, COTTAM GL: Dehydroisoandrosterone prevention of autoimmune disease in NZB/ W Fl mice: lack of an effect on associated immunological abnormalties. Biechimica Biephysica Acta (1989) 992:265.
   Google Scholar
• VAN VOLLENHOVEN RF, MCDEVITT HO: Studies of the treatment of nephritis in NZB/NZW mice with dehydroepiandro-sterone. Arthritis Rheum. (1992) 35:S207. Abstract.
   Google Scholar
• VAN VOLLENHOVEN RE ENGLEMAN EG, MCGUIRE JL: Dehydroepiandrosterone in systemic lupus erythematosus: Results of a double-blinded, placebo-controlled, randomized clinical trial. Arthritis Rheum. (1995) 38:1826-1831. ••The first controlled study of DHEA inSLE. The results indicate that DHEA 200 mg/day for 3 months improves overall SLE activity and decreases the number of flares.
   Google Scholar
• VAN VOLLENHOVEN RE PARK JL, GENOVESE MC et al: A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus. Lupus (1999) 8:181-187. DHEA 200 mg/day was added to high-dose corticosteroids for severe SLE in a small, double-blind study. The results suggest that DHEA counteracts the osteoporotic effect of high-dose corticosteroid treatment.
   Google Scholar
• PETRI M, LAHITA R, MCGUIRE J et al: Results of the GL701 (DHEA) multicenter steroid-sparing SLE study. Arthritis Rheum. (1997) 40:S327. ••Results from the pivotal multi-centre studyof DHEA in corticosteroid-dependent SLE. The results indicate that in patients with active SLE, DHEA 200 mg/day allows significant corticosteroid dose reductions.
   Google Scholar
• VAN VOLLENHOVEN R1 MORABITO LM, ENGLEMAN EG et al: Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. J. Rheumatel. (1998) 25:285-289. •An uncontrolled observational study of DHEA in SLE, suggesting that treatment with DHEA gives incremental benefits over a 1-year treatment period with respect to disease activity and corticosteroid requirement.
   Google Scholar
• BARRY NN, MCGUIRE JL, VAN VOLLENHOVEN RF: Dehydroepiandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response. J. Rheumatel (1998) 25:2352-2356. •Only a weak relationship was found between DHEA dosages and clinical effects, but the data suggest that an optimal serum level of DHEA-sulfate is seen at around 1 mg/ml.
   Google Scholar
• WOLKOWITZ OM, REUS VI, ROBERTS E et al.: Dehyroepiandrosterone (DHEA) treatment of depression. Biel. Psychiatry (1997) 41:311–318.
   PubMed Web of Science ®Google Scholar
• LABRIE E DIAMOND P, CUSAN L, COMEZ JL et al: Effect of 12-month dehydroepiandrsterone replacement therapy on bone, vagina, and endometrium in postmenopausal women. J. Clin. Ender/ilia Metab. (1997) 82:3498–3505.
   Google Scholar
• PARASRAMPURIA J, SCHWARTZ K, PETESCH R: Quality control of dehydroepiandrosterone dietary supplement products. JAMA (1998) 280:1565. Abstract.
   Google Scholar
• BELONGIA EA, HEDBERG CW, •• GLEICH GJ et al.: An investigation of the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. N Engl. Med. (1990) 323:357–365.
   Google Scholar
• MEASE PJ, MERRILL JT, LAHITA RG et al.: GL701 (prasterone, dehydroepiandro-sterone) improves systemic lupus erythematosus. ACR annual meeting (2000). Abstract. ••The first report of the GL95-02 multi-centre clinical trial of DHEA 200 mg/day versus placebo in SLE. A 1-year study of — 300 patients, showing a greater percentage of patients in the active treatment group met the predefined clinical response criteria.
   Google Scholar
• MEASE PJ, GINZLER EM, GLUCK OS et al.: Improvement in bone mineral density in steroid-treated SLE patients during treatment with GL701 (GL701 (prasterone, dehydroepiandrosterone). ACR annual meeting (2000). Abstract. •The first report of the GL95-02 multi-centre clinical trial of DHEA 200 mg/day versus placebo in SLE. A 1-year study of — 300 patients, showing a greater percentage of patients in the active treatment group met the predefined clinical response criteria.
   Google Scholar
• CHANG, DM, LAN JL, LIN HY, LUO SF: GL701 (prasterone, dehydroepiandrosterone) significantly reduces flares in female patients with mild to moderate systemic lupus erythematosus (SLE). ACR annual meeting (2000). Abstract. ••This large single-center study showed asignificant decrease in the number of SLE flares under DHEA treatment.
   Google Scholar
• ARLT W, CALLIES F, VAN VLIJMEN JC et al.: Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl. J. Med. (1999) 341:1013–1020.
   Google Scholar
• HUNT PJ, GURNELL EM, HUPPERT FA et al: Improvement in mood and fatigue after dehydroepiandrosterone replacement in Addison's disease in a randomized, double blind trial. ..J. Clin. Endocrinol Metab. (2000) 85:4650–4656.
   PubMed Web of Science ®Google Scholar
• SVEC E PORTER JR: The actions of exogenous dehydroepiandrosterone in experimental animals and humans. Proc. Soc. Exp. Biol. Med. (1998) 218:174–191.
   Google Scholar